Advances in Clinical Chemistry, Volume 133 in this ongoing series, examines physiologic and pathophysiologic biochemistry and their impacts on Clinical Chemistry testing and design. Molecular mechanisms of disease processes are highlighted in the context of traditional, current, and emerging technologies, and advances in the development of improved diagnostic and predictive biomarkers are examined, especially those targeting early and emerging diseases. Specific chapters in this new release include Drug Induced Renal Injury (DIRI) Biomarkers, Unveiling tobacco markers in exhaled breath, Advances in small extracellular vesicle analysis, Piezoelectric Sensors in Point-of-Care Testing, Mitochondrial myopathy biomarkers, and Hormonal and Metabolic Biomarkers in Long COVID.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Contributors - p. iv 7. Preface - p. xi 8. Chapter One: Drug induced renal injury (DIRI) biomarkers - p. 1 9. Chapter Two: Unveiling tobacco markers in exhaled breath - p. 45 10. Chapter Three: Advances in small extracellular vesicle analysis - p. 79 11. Chapter Four: Piezoelectric sensors in point-of-care testing - p. 127 12. Chapter Five: Mitochondrial myopathy biomarkers - p. 161 13. Chapter Six: Hormonal, metabolic and metabolomic biomarkers in long COVID - p. 217 14. Index - p. 285
Advances in Clinical Chemistry, Volume 133 in this ongoing series, examines physiologic and pathophysiologic biochemistry and their impacts on Clinical Chemistry testing and design. Molecular mechanisms of disease processes are highlighted in the context of traditional, current, and emerging technologies, and advances in the development of improved diagnostic and predictive biomarkers are examined, especially those targeting early and emerging diseases. Specific chapters in this new release include Drug Induced Renal Injury (DIRI) Biomarkers, Unveiling tobacco markers in exhaled breath, Advances in small extracellular vesicle analysis, Piezoelectric Sensors in Point-of-Care Testing, Mitochondrial myopathy biomarkers, and Hormonal and Metabolic Biomarkers in Long COVID.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. Contributors - p. iv 7. Preface - p. xi 8. Chapter One: Drug induced renal injury (DIRI) biomarkers - p. 1 9. Chapter Two: Unveiling tobacco markers in exhaled breath - p. 45 10. Chapter Three: Advances in small extracellular vesicle analysis - p. 79 11. Chapter Four: Piezoelectric sensors in point-of-care testing - p. 127 12. Chapter Five: Mitochondrial myopathy biomarkers - p. 161 13. Chapter Six: Hormonal, metabolic and metabolomic biomarkers in long COVID - p. 217 14. Index - p. 285
